Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology company, announced its financial results for the year ended December 31, 2025, along with significant business developments. The company reported a net loss attributable to common stockholders of $19.4 million, or $(1.91) per share, compared to a net loss of $11.1 million, or $(1.51) per share for the previous year. Operating expenses increased to $24.2 million from $17.1 million in 2024, primarily driven by heightened research and development activities related to its lead product, SER-252.

In a notable advancement, Serina received FDA clearance for its Investigational New Drug (IND) application for SER-252, which is aimed at treating advanced Parkinson's disease. The company has initiated a Phase 1b trial for SER-252, marking a critical step in its clinical development. Additionally, Serina successfully closed a private placement financing of up to $30 million, which will bolster its financial position and support upcoming clinical milestones. The financing includes a structure that allows for potential additional proceeds through warrant coverage.

CEO Steve Ledger emphasized the company's commitment to advancing SER-252 into the clinic while strengthening its balance sheet. With the first patient dosed in the registrational trial and substantial financing secured, Serina is poised to achieve significant value-creating milestones in 2026. The company also highlighted its ongoing At-the-Market (ATM) equity program, which has generated gross proceeds of approximately $12.9 million to date.

Overall, Serina's strategic initiatives and recent financing efforts position the company favorably for future growth and operational execution in the competitive biotechnology landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.